Avalo Therapeutics, Inc. (AVTX) · Nov 5, 2026 · Share issuance
$200M ATM — Up to $200M in common-stock sales; no obligation to sell
Avalo Therapeutics launched a $200 million ATM offering, replacing its unused TD Cowen facility and preserving capital flexibility for Phase 3 development at the cost of potential dilution.
Avalo is a clinical-stage biotech moving its lead drug candidate, abdakibart, toward a registrational Phase 3 program in hidradenitis suppurativa while developing a second IL-1β antibody, AVTX-010. Its latest reported balance sheet showed $472.2 million in cash, cash equivalents and investments, with management expecting funding into 2029.
The filing creates financing capacity, not immediate cash. Avalo signed a new Jefferies at-the-market facility allowing up to $200 million of common-stock sales. 〔0〕 The company is not required to sell any shares, and Jefferies is not required to place a minimum amount. 〔1〕
This is a larger backstop than the facility it replaces, but the old program was not being used. Avalo terminated its TD Cowen ATM, which had a $75 million authorization; the company reported no sales under that program during the first half of 2026. The new authorization is therefore a meaningful expansion of potential equity capacity, but not evidence that $200 million has been raised or that a near-term liquidity gap has opened.
The trade-off is future dilution rather than current balance-sheet relief. Shares can be sold gradually at management’s discretion, with Jefferies receiving up to a 3% commission. 〔2〕 That flexibility could help fund a costly Phase 3 buildout without waiting for a conventional offering, but it also gives the company a large new source of potential share issuance while existing cash already extends well beyond the next year.
The filing modestly complicates the capital story rather than changing the drug story. It does not add clinical data, alter the Phase 3 plan, or provide proceeds; it mainly preserves optionality for development spending. The market’s key follow-through will be whether Avalo actually draws on the facility and how much capital the Phase 3 program ultimately requires.
Bottom line: Avalo has secured a much larger equity-financing tool, but not new cash today. With runway already extending into 2029, the filing is mainly a dilution risk and capital-flexibility signal—not a fundamental change to the pipeline story.
Phase 3 HS program initiation, first half 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!